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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: The USA Food and Drug Administration (FDA) issued warnings regarding
the use of antipsychotics in patients with dementia in 2003 and 2005. We aimed to study
the dose and duration of antipsychotic treatment in dementia, and to examine whether physi-
cians’ prescription behaviors changed after the FDA warnings.
Methods: Medical charts of outpatients who had Alzheimer’s disease, vascular dementia, or
mixed dementia were reviewed. Patients must have achieved a clinically stable state for at
least 4 weeks after receiving antipsychotic treatment for agitation or psychosis. Demo-
graphics, clinical correlates, and duration of antipsychotic treatment were compared among
different antipsychotic groups. Because the quetiapine group had the largest sample size,
the optimal dose and duration of quetiapine treatment were compared among three time
periods (before 2003, 2003e2005, after 2005).
Results: Stable state was achieved in 215 patients (80 had Alzheimer’s disease, 117 vascular
dementia, and 18 mixed dementia). Most patients (177) took quetiapine, 25 took risperidone,
and 13 took sulpiride. The whole sample had a long total duration of antipsychotic treatmentave no conflicts of interest relevant to this article.
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148 Y.-T. Lin et al.(median 525 days,mean 707days). Themedian dose and total duration of antipsychotic treatment
were 1.0 mg/day and 238 days for risperidone, 100 mg/day and 390 days for sulpiride, and 25 mg/
day and 611 days for quetiapine, respectively. The optimal dose and total duration of quetiapine
treatmentdecreased significantlyafterFDAwarning in2005,althoughtheduration remained long.
Conclusion: The optimal doses of antipsychotics were not higher than those of western reports,
but the total duration of antipsychotic treatment was quite long. Although our study suggests
the prescription dosage and duration of antipsychotic treatment decreased significantly after
FDA warning in 2005, the duration of treatment was still long. Given the serious safety concerns,
more effort should be made to avoid unnecessary and prolonged prescription.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The prevalence of dementia increases with age, and it was
estimated that 24.3 million people had dementia worldwide
in 2005 and the number will double every 20 years, reaching
over 80 million by 2040.1 Dementia is a deteriorating
disorder accompanied with various distressing neuropsy-
chiatric symptoms. During the course of Alzheimer’s
disease (AD), up to 90% of patients develop the behavioral
and psychological symptoms of dementia, of which
psychosis and agitation present in more than half of all
patients.2e4 Furthermore, dementia-related psychosis and
agitation have been reported to be associated with
decreased quality of life,5 more rapid cognitive decline,6
increased burden on caregivers,7 early institutionaliza-
tion,8 and even higher mortality.9,10
Although no pharmacotherapy has been approved by the
US Food and Drug Administration (FDA) for patients with
dementia-related agitation or psychosis, off-label use of
antipsychotic agents is common. Before 2005, antipsychotic
agents were recommended as the first-line pharmaco-
therapy for agitated dementia with delusions and as the
high-second line for agitated dementia without delusions.11
Atypical antipsychotic agents are preferred over typical
antipsychotic agents as they have fewer extrapyramidal
side effects. Many clinical trials revealed a better efficacy
for antipsychotic agents as compared with placebo, but
there were also inconsistent results. A meta-analysis of 15
placebo-controlled, double-blind, parallel-group trials
involving four atypical antipsychotic agents showed only
modest efficacy on rating scales for risperidone and aripi-
prazole, but not for olanzapine.12 Another meta-analysis
focusing on aggression and psychosis in AD showed signifi-
cant improvements in aggression with risperidone and
olanzapine treatment, but only significant improvements in
psychosis with risperidone treatment.13 Unfortunately,
antipsychotic agents were noted to be associated with
increased risk for cerebrovascular accidents in elderly
demented patients, so the FDA issued a “Dear Healthcare
Professional” letter in April 2003.14 Further, meta-analysis
found significantly increased mortality rate with 6- to 12-
week atypical antipsychotic treatment in patients with
dementia.15 Therefore, in April 2005, the FDA issued
a black box warning that antipsychotics could increase
mortality risk in demented patients.16 Considering both the
efficacy and adverse effects, clinicians face a decision
dilemma when treating patients with agitation or psychosis.
Nonpharmacological interventions may be tried first, andwhen necessary, the lowest dosage and shortest duration of
antipsychotic agent treatment are recommended.
However, data about physicians’ prescribing behaviors in
real life practice are missing in Taiwan. Hence we con-
ducted a study to investigate the dosage and duration of
antipsychotic treatment in demented outpatients with
agitation or psychosis. Specifically, we wanted to investi-
gate: (1) the dosage and duration of antipsychotic treat-
ment in demented outpatients with agitation or psychosis;
and (2) whether the prescription behaviors changed after
FDA warnings in 2003 and 2005.Methods
Patients
This was a retrospective study using the chart review
method. Elderly patients who were diagnosed as having
dementia at neurology and psychiatric clinics were
sampled in an exhaustive way according to predefined
criteria in the National Taiwan University Hospital. In the
first step, all candidate patients were selected from the
hospital database if they had a diagnosis of dementia
between January 2006 and December 2007. In the second
step, patients’ eligibility into this study was evaluated by
four senior psychiatric residents knowledgeable in the
diagnosis and management of dementia through chart
review. To be included, each patient must meet five
inclusion criteria: (1) diagnosis of AD, VaD, or mixed
dementia by a neurologist or a psychiatrist; (2) a mini-
mental status examination score between 10 and 26; (3)
being prescribed an antipsychotic agent indicated solely
for dementia-related agitation or psychosis at outpatient
clinics; (4) not receiving any other antipsychotic agent
previously or concurrently; and (5) having achieved a pre-
defined “stable state” (definition below). The diagnosis of
AD and VaD was based on DSM-IV-TR.17 Mixed dementia
was defined as cognitive decline sufficient to impair
independent functioning in daily life resulting from the
coexistence of AD and cerebrovascular pathology, docu-
mented either by clinical criteria or by neuroimaging
findings.18 Candidate patients were excluded if they had
a diagnosis of a primary psychotic disorder, delirium, other
dementias (such as Lewy body dementia) that warranted
the use of antipsychotic agents, or other conditions (such
as concurrent medical disease, medications, substance
abuse) contributing to agitation or psychosis.
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stable state, duration of stable state, and total
duration of antipsychotic treatment
Medical chart review was done between June 2008 and
September 2008. “Stable state” was defined as the first
period of time after initiation of antipsychotic treatment
during which: (1) there had been at least two clinical visits
at an interval of at least 4 weeks; (2) a constant dose of
antipsychotic agent had been maintained throughout; and
(3) clinical improvements were achieved and documented in
the charts. A similar definition has been employed to study
the optimal dose of antipsychotic treatment in schizo-
phrenia.19 This definition reflected both clinical efficacy and
tolerability of treatment. The at-least-4-week duration is
considered adequate since expert opinions recommend
discontinuing or switching an antipsychotic agent after 2 to
4 weeks when patients are no longer benefiting from it.11,20
A stable state ended when target antipsychotic agent was
either discontinued, changed in dosage, or added with
another antipsychotic agent to control symptoms. “Optimal
dose” was defined as the constant dose of an antipsychotic
agent during the stable state. “Time to stable state” was
defined as the time elapsed from the initial prescription of
target antipsychotic agent to the beginning of stable state.
“Duration of stable state” was counted from the beginning
to the end of stable state, or from the beginning to the time
of chart review if patients had not left the stable state.
Total duration of target antipsychotic treatment was coun-
ted from the beginning of the stable state to the time of
discontinuation of target antipsychotic agent or the time of
chart review, whichever came first. The main reason to
adopt the definition of stable state was to examine clearly
how long the antipsychotic agent was kept for a stabilized
patient until different outcome (for example, psychotic
symptoms ameliorated or aggravated).
In the sample, some patients might receive a diagnosis
of dementia in the 1990s and were prescribed of an anti-
psychotic agent for dementia-related agitation/ psychosis
in the 1990s too. Because the chart review time was
between June 2008 and September 2008, these patients
might have long duration of stable state and total duration
of antipsychotic treatment if the antipsychotic agent was
continuously prescribed.
Data extraction
The data of the enrolled patients were extracted through
medical chart review by three senior psychiatric residents
knowledgeable about dementia. Discussions were made for
the first three to five charts reviewed by each resident to
reach consensus and to ensure the quality and consistency
of the review process. Eligibility of the recruited patients
and correctness of the collected data were double checked
by the fourth senior psychiatric resident (Y.T.L.). A geriatric
psychiatry specialist (T.J.H.) supervised the whole work. If
there were any doubt, the team would discuss to reach final
consensus.
A total of 695 candidate dementia patients were
retrieved from the hospital database, and 217 patients
were eligible for final analysis. Of the 478 excludedpatients, 130 were diagnosed for other dementia subtypes,
212 failed to achieve stable states, 69 had compromising
medical conditions affecting the use of antipsychotic
agents, 38 had other concurrent reasons contributing to
behavioral symptoms, and the remaining 29 were excluded
for other reasons, such as use of two antipsychotic agents
or no dementia-related behavioral symptoms. There were
no statistically significant differences on sex or age
between the 217 included and 478 excluded patients (or
212 patients who failed to achieve stable state; p> 0.10).
Demographic data, dementia subtype, symptom profile
and severity, concurrent medications, and smoking and
alcohol use were recorded. Reviewers determined the
stable state, optimal dose, time to stable state, and total
duration of antipsychotic treatment. The severity of
agitation and psychosis was defined as follows: “mild to
moderate” referred to symptoms that usually could be
calmed down by caregivers, but sometimes disturbing;
“severe” indicated significant suicidal or violence risks, or
conditions necessitated hospitalization; and “moderate to
severe” stood for severity between the former 2 conditions.
If the severity couldn’t be judged, “unknown” severity was
coded. The study was approved by the institutional review
board of National Taiwan University Hospital.
Statistical methods
Enrolled patients were grouped by types of antipsychotic
agents they took during stable states. Demographic data
and clinical correlates were compared among groups by
using Chi-square test (or Fisher exact test) for categorical
variables and ANOVA for continuous variables. For time to
stable state, duration of stable state and total duration of
target antipsychotic treatment, KruskaleWallis test and
ManneWhitney test were used. Since the quetiapine group
had the largest sample size, we used it to investigate
whether there were changes on physicians’ prescription
behaviors before and after the FDA’s warnings in 2003 and
2005. Thereafter we subdivided patients into three cohorts
according to the starting points of target antipsychotic
agents: Cohort 1: starting points before April 30, 2003;
Cohort 2: starting points between May 1, 2003 and April 30,
2005; Cohort 3: starting points between May 1, 2005 and
April 30, 2006. Since the chart review began around June
2008, each cohort could be observed and followed-up for 2
years. Duration of stable state and total duration of que-
tiapine treatment were counted and truncated to 2 years
(i.e., the maximal value would be 730 days). KruskaleWallis
test and ManneWhitney test were used for comparison
among and between groups. Because there were data of
behavioral pathology in Alzheimer’s disease (BEHAVE-AD)
recorded in the charts for 25 patients at the time near the
beginning of antipsychotic agent treatment, we used these
data to examine the correlation between severity rating
defined in this study and the global rating score of BEHAVE-
AD (4-point scale, rated from 0e3) by Kendall’s tau.
Results
A total of 217 patients had achieved stable state, and 215 of
them comprised the three antipsychotic groups (Table 1).
Table 1 Demographic data and clinical correlates of three antipsychotic groups.
Characteristics Total
(NZ 215)
Risperidone
(NZ 25)
Sulpiride
(NZ 13)
Quetiapine
(NZ 177)
c2 or F
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (y) 77.5 (8.1) 73.1 (10.1)z 75.1 (6.3) 78.3 (7.7) 5.16y
Duration of illness (y) 2.8 (2.5) 2.9 (3.0) 1.7 (1.1) 2.9 (2.5) 1.36
Mini-mental status
examination score
14.7 (6.5) 16.3 (6.8) 18.6 (4.3) 14.3 (6.4) 1.64
N (%) N (%) N (%) N (%)
Sex (female) 128 (59.5) 11 (44.0) 7 (53.8) 110 (62.1) 3.18
>9 y of education 57 (26.5) 9 (36.0) 3 (23.1) 45 (25.4) 2.821
Neurology clinics 168 (78.1) 16 (64.0)x 4 (30.9)z 148 (83.6) 23.11y
Diagnosis 10.77*
Alzheimer’s disease 80 (37.2) 9 (36.0) 0 (0.0) 71 (40.1)
Vascular dementia 117 (54.4) 15 (60.0) 10 (76.9)z 92 (52.0)
Mixed dementia 18 (8.4) 1 (4.0) 3 (23.1) 14 (7.9)
Severity 6.40
Unknown 32 (14.9) 3 (12.0) 0 (0.0) 29 (16.4)
Mild to moderate 94 (43.7) 12 (48.0) 7 (53.8) 75 (42.4)
Moderate to severe 79 (36.7) 9 (36.6) 4 (30.9) 66 (37.3)
Severe 10 (4.7) 1 (4.0) 2 (15.4) 7 (4.0)
Concurrent medications
Valproate 10 (4.7) 0 (0.0) 0 (0.0) 10 (5.6) 2.25
Antidepressants 52 (24.5) 8 (32.0) 3 (23.1) 41 (23.2) 0.94
Benzodiazepines 18 (8.4) 2 (8.0) 2 (15.4) 14 (7.9) 0.89
Cholinesterase inhibitors 46 (21.4) 4 (16.0) 0 (0.0) 42 (23.7) 4.54
Memantine 8 (3.7) 0 (0.0) 0 (0.0) 8 (4.5) 0.41
*p< 0.05, yp< 0.01: comparisons among the 3 antipsychotic groups; zp< 0.01, xp< 0.05: vs. quetiapine group.
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were excluded due to very small group size. There were
significant differences in age, diagnosis, and distribution of
clinics among the three groups.
Severity coded by methods defined in this study had
a fair correlation with BEHAVE-AD scores (Kendall’s tau
b correlation coefficientZ 0.566, pZ 0.001), supporting
an acceptable accuracy of data coding. Table 2 shows the
optimal dose, time to stable state, duration of stable state
and total duration of target antipsychotic treatment.
Although the definition of stable state only requires
a duration of at least 4 weeks, the actual duration of
“stable state” usually is much longer than 4 weeks. ForTable 2 Optimal dose, time to stable state, duration of stable st
antipsychotic groups.
Total
(NZ 215)
Risperido
(NZ 25
Median Mean (SD) Median Mea
Optimal dose (mg/d) d d 1.0 1.0
Time to stable state (d) 0 21 (47) 0 5
Duration of stable state (d) 245 374 (385) 168 215
Total duration of target
antipsychotic treatment (d)
525 707 (587) 238 488
*p< 0.05, yp< 0.01: comparisons among the 3 antipsychotic groups (K
test); zp< 0.01: vs. risperidone (ManneWhitney test).example, the range of stable state for the 215 patients was
42 to 2703 days, with 99.5% of the patients having a stable
state of 8 weeks, 90.2% 12 weeks and 82.8% 16 weeks.
This means that the majority of this sample had been
stabilized for 3 to 4 months, rather than 1 month only. The
effectiveness of the antipsychotic agents was also reflected
by a long median and mean duration of stable state (median
245 days, mean 374 days).
For the whole sample, there was not only a long duration
of stable state, but also a long total duration of target
antipsychotic treatment (median 525 days, mean 707 days;
Table 2). The median time to stable state was 0 days for the
whole group, indicating >50% of the patients could get theate and total duration of antipsychotic treatment of the three
ne
)
Sulpiride
(NZ 13)
Quetiapine
(NZ 177)
H
n (SD) Median Mean (SD) Median Mean (SD)
(0.5) 100.0 126.9 (104.8) 25.0 43.8 (56.0)
(13)x 28 39 (40) 0 22 (50)x 11.973y
(157) 211 398 (705) 266 394 (373)z 8.156*
(566) 390 792 (978) 611 732 (550)z 8.237*
ruskaleWallis test); xp< 0.01: vs. sulpiride group (ManneWhitney
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cant differences on time to stable state (p< 0.01), duration
of stable state (p< 0.05) and total duration of antipsy-
chotic treatment (p< 0.05) among the three groups. Post-
hoc analysis found that sulpiride group had significantly
longer time to stable state than the other two groups, while
the risperidone group had significantly shorter duration of
stable state and total duration of antipsychotic treatment
than the quetiapine group (Table 2).
For a total of 176 patients whose reasons for leaving
stable state were well recorded, Table 3 shows the
respective duration of stable state and total duration of
antipsychotic treatment related to different reasons. Even
for those who had achieved satisfactory condition, the
median duration of stable state was longer than 3 months,
and the median total duration of antipsychotic treatment
was >1 year. The cohort effects of prescription behaviors in
the quetiapine group are shown in Table 4. Cohort 3 had
significantly lower dose and shorter duration of quetiapine
treatment than Cohort 1 or Cohort 2 (p< 0.01). When
Cohort 3 was compared to Cohort 2, the reduction for
optimal dose was 47.7% [Z (64.2 e 33.6)/64.2], for dura-
tion of stable state 24.2%, and for total duration of anti-
psychotic treatment 18.7%.Discussion
We aimed to study the optimal dose and duration of anti-
psychotic treatment for dementia-related agitation and/or
psychosis, and to examine whether these prescription
behaviors changed or not after the FDA warnings in 2003
and 2005. The main findings from this particular sample
were: (1) the optimal doses of antipsychotics were similar
to those of western reports, except that the dose of que-
tiapine was slightly lower; (2) the sulpiride group had
longest time to reach stable state, while the risperidone
group had the shortest duration of stable state and total
duration of antipsychotic treatment; and (3) overall, the
duration of stable state and total duration of antipsychotic
treatment were long, but the dose and duration of anti-
psychotic treatment decreased significantly after 2005.
In addition to total duration of antipsychotic treat-
ment, we also defined “stable state” and “optimal dose”
in order to investigate physicians’ prescribing behaviors in
a clearer manner. Similar definitions have been applied to
schizophrenia patients to study the optimal dose ofTable 3 Duration of stable state related to different reasons fo
Reason for leaving stable state N (%)
Me
Loss of efficacy (d) 71 (40.3) 245
Achieving satisfactory condition (d) 36 (20.5) 172
Adverse reactions (d) 29 (16.5) 218
Loss of follow-up (d) 28 (15.9) 121
Death or new medical condition (d) 4 (2.3) 186
Other reason (d) 8 (4.5) 349
Total (d) 176 (100.0) 245antipsychotics, which yielded important findings for
Taiwanese population when compared to Caucasian
analogs.19,21 To make the definition more valid, we further
required that the stable period should be verified by two
clinical visits at adequate interval and improvements
should be documented. The findings that 99.5% of the 215
patients had a stable state of 8 weeks, 90.2% 12 weeks
and a long median (mean) duration of stable state (245
days) support the efficacy of optimal dose and clinical
validity of “stable state” in our study. In theory, by
applying these inclusion criteria, we identified a group of
demented patients who were responders to antipsychotic
treatment. By adopting the concept of “duration of stable
state”, “reasons for leaving stable state”, and “total
duration of antipsychotic treatment” together, we can
investigate physicians’ prescribing behaviors under
different situations in a better manner than previous
studies, which usually reported total duration of antipsy-
chotic treatment only.
According to previous clinical trials, target doses of
antipsychotic agents for agitation and/or psychosis in
patients with AD were recommended as 0.5 to 1.5 mg/day
for risperidone and 50 to 200 mg/day for quetiapine.22 In
a recent rater-blinded head-to-head randomized study
comparing both antipsychotic agents in treating behavioral
symptoms of dementia, Rainer et al reported that the drugs
were equally effective, and the mean dose was 0.9 mg/day
for risperidone and 77 mg/day for quetiapine.23 In the
CATIE-AD study, the mean quetiapine dose (57.0 mg/day)
was higher than that in our study (37.5 mg/day for AD
patients).24 Overall, the optimal dose of risperidone in our
study was similar to the reported doses, but the mean
quetiapine dose was somewhat lower. Several factors may
account for the differences. First, our recruited subjects
were outpatients rather than institutionalized or hospital-
ized patients, whose conditions are usually severer and thus
require higher doses of treatment. Second, patients with
poor response to antipsychotic agents were not included in
our study, but this group of patients constituted a portion of
subjects in clinical trials and was usually prescribed of
higher doses. Third, most of our patients had mild to
moderate degree of symptom severity, in contrast to
moderate to severe degree of severity in the CATIE-AD
study, although both studies recruited outpatients only.
The median time to stable state of all 215 patients was
0 days indicates that at least 50% of the patients could be
stabilized by a dose not larger than recommendedr leaving stable state.
Duration of
stable state
Total duration of target
antipsychotic treatment
dian Mean (SD) Median Mean (SD)
346 (291) 716 858 (583)
244 (193) 381 634 (585)
329 (300) 582 666 (478)
313 (515) 200 592 (753)
412 (493) 702 688 (586)
461 (281) 547 682 (575)
374 (385) 589 726 (600)
Table 4 Comparisons of optimal dose, duration of stable state, and total duration of antipsychotic treatment among three
quetiapine cohorts.
Cohort 1 (NZ 21) Cohort 2 (NZ 43) Cohort 3 (NZ 40) H
Median Mean (SD) Median Mean (SD) Median Mean (SD)
Optimal dose (mg/d) 50.0 71.4 (86.3)y 25.0 64.2 (77.7)y 25.0 33.6 (34.0) 11.98*
Duration of stable state (d) 266 364 (242) 513 472 (257) 349 358 (224) 4.69
Total duration of target
antipsychotic treatment (d)
730 683 (127)y 730 668 (148)y 719 543 (235) 12.47*
Cohort 1: starting points before April 30, 2003; Cohort 2: starting points between May 1, 2003 and April 30, 2005; Cohort 3: starting points
between May 1, 2005 and April 30, 2006. *p< 0.01: comparison among the 3 groups (KruskaleWallis test); yp< 0.01: vs. cohort 3
(ManneWhitney test).
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time to stable state was 0 days for both risperidone and
quetiapine group, but 28 days in the sulpiride group. One
possible explanation is that sulpiride is not commonly used
by physicians, and virtually not available in many western
countries, so no recommended dose exists in most guide-
lines. The physicians had to titrate the dose in order to
reach stable state. In contrast, the risperidone group had
the shortest total duration of antipsychotic treatment and
duration of stable state. Several factors may account for
this finding. First, risperidone may be relatively more
effective in the treatment of agitation/psychosis. This is
supported by recent meta-analyses.12,13 Second, risper-
idone may be associated with significant adverse effects
that limit its continuous use.12,13 Third, risperidone was the
first antipsychotic agent to get an FDA warning and physi-
cians are more aware of its adverse effects.14
The overall long duration of antipsychotic treatment was
also reflected by long duration of treatment related to
different reasons for leaving stable state (Table 3). Even for
the reason of “achieving satisfactory condition”, the dura-
tion of stable state was long (median: 172 days, mean 244
days), and the total duration of antipsychotic treatment was
even longer (median up to 1 year, mean up to 1.7 years). The
duration of treatment for patients leaving stable state due to
other reasons was usually longer than that for patients
leaving stable state due to “achieving satisfactory condi-
tion”. The good news is that the dose and duration of anti-
psychotic treatment decreased significantly after the FDA
warning in 2005, as shown in Table 4. For a 2-year observa-
tion, compared to Cohort 2, Cohort 3 had a mean dose
reduction of 47.7% and a mean total duration reduction of
18.7%. The changes are significant, although the median and
mean total duration of treatment in cohort 3 were still 719
days and 543 days within a 730-day observation period. Our
preliminary study using a national claim dataset from 2001 to
2007 also found that the prescription duration of antipsy-
chotics in patients with dementia was still long and the
prescribed dose did not decrease significantly.25
Although the morbidity and mortality risks associated
with antipsychotic treatment occur shortly within 30 days
of prescription,26 a placebo-controlled study found that the
differences in mortality between the continuation group
and placebo group were even more pronounced 24 and 36
months later.27 With increasing evidence of the risks of
antipsychotics in elderly dementia, practice guidelinesgenerally recommended regular review of the benefits and
harms of treatment and frequent trials of dose reduction or
discontinuation after a period of time of stabilization, for
example, no more than 12 weeks.11,28e30
Our study could not address why physicians maintained
antipsychotic agents long without trials of changing the
dose. There were several possible reasons, for example,
the suboptimal therapeutic effects of antipsychotics,
symptom aggravation after tapering the dose,31 the ineffi-
cacy or unavailability of nonpharmacological intervention,
inadequate family support, the favorable sedative effects
of antipsychotics for insomnia, and the differential risk
associated with different antipsychotics. Our study found
that quetiapine was the most frequently prescribed and
associated with longest median total duration of treat-
ment. Low dose quetiapine has a good hypnotic effect and
very few extrapyramidal side effects, which help agitated
patients sleep better and decrease the caregiver burden.
Several physicians admitted that they prescribed low dose
quetiapine because of this reason (personal communica-
tion). A recent population-based cohort study found that,
compared with risperidone, users of haloperidol had an
increased risk of mortality and users of quetiapine
a decreased risk.32 Future studies are needed to find factors
that predispose to continuous use of antipsychotics, and
new treatment with better efficacy and favorable side
effect profile should be developed.
There are several limitations of our study. First, it was
a retrospective study and data were collected from medical
charts. Documentation in charts might be inadequate or
incomplete. Symptom profile, clinical severity, and treat-
ment response had to be inferred. Information about
adherence to treatment was often unavailable. Second,
only the database of one hospital was studied. Therefore
the results may not be generalizable. Finally, only
responders of antipsychotic agents were studied, so the
results could not be generalized to all demented patients
with agitation or psychosis.
In conclusion, our study suggests that the mean dose and
duration of antipsychotic treatment decreased significantly
after the FDA warning in 2005 in this national medical
center, but the duration remains long. This has important
clinical implication because antipsychotics are associated
with significant morbidity and mortality risks. Regular
review of prescriptions and early trials of withdrawing
antipsychotic agents should be advocated.
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